582 reports of this reaction
3.1% of all AMLODIPINE BESYLATE AND VALSARTAN reports
#2 most reported adverse reaction
HYPERTENSION is the #2 most commonly reported adverse reaction for AMLODIPINE BESYLATE AND VALSARTAN, manufactured by Novartis Pharmaceuticals Corporation. There are 582 FDA adverse event reports linking AMLODIPINE BESYLATE AND VALSARTAN to HYPERTENSION. This represents approximately 3.1% of all 18,550 adverse event reports for this drug.
Patients taking AMLODIPINE BESYLATE AND VALSARTAN who experience hypertension should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPERTENSION is moderately reported among AMLODIPINE BESYLATE AND VALSARTAN users, representing a notable but not dominant share of adverse events.
In addition to hypertension, the following adverse reactions have been reported for AMLODIPINE BESYLATE AND VALSARTAN:
The following drugs have also been linked to hypertension in FDA adverse event reports:
HYPERTENSION has been reported as an adverse event in 582 FDA reports for AMLODIPINE BESYLATE AND VALSARTAN. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPERTENSION accounts for approximately 3.1% of all adverse event reports for AMLODIPINE BESYLATE AND VALSARTAN, making it one of the most commonly reported side effect.
If you experience hypertension while taking AMLODIPINE BESYLATE AND VALSARTAN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.